eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Quality of life of patients treated for stage IV breast cancer. Multidimensional assessment and examination of determining factors

Juan Ignacio Arraras
1, 2, 3
,
Jose Juan Illarramendi
1, 3
,
Ana Manterola
2, 3
,
Uxue Zarandona
2, 3
,
Berta Ibañez
4
,
Andrew Bottomley
5
,
Lucia Teijeira
1, 3
,
Ignacio Visus
2, 3
,
Susana de la Cruz
1, 3
,
Marta Barrado
2, 3
,
Ruth Vera
1, 3

  1. Medical Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain
  2. Radiotherapeutic Oncology Department, Hospital Universitario de Navarra, Pamplona, Spain
  3. Institute for Health Research of Navarre (IdiSNA), Pamplona, Spain
  4. Methodology Unit, Navarrabiomed, RICAPPS, Spain
  5. Bottomley Consulting Group, Brussels, Belgium
Contemp Oncol (Pozn) 2024; 28 (4): 350–357
DOI: https://doi.org/10.5114/wo.2024.147006
Online publish date: 2025/01/15
Article files
- Quality of life (1).pdf  [0.11 MB]
- Quality of life - Supplementary Table 1.pdf  [0.10 MB]
Get citation
 
PlumX metrics:
 
1. Seltzer S, Corrigan M, O’Reilly S. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer. Exp Mol Pathol 2020; 14: 104404. DOI: https://doi: 10.1016/j.yexmp.2020.104404.
2. Cardoso F, McCartney A, Ponti A, et al. European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care. Eur J Cancer 2023; 187: 105-113.
3. Harbeck N, Gnant M. Breast cancer. Lancet 2017; 389: 1134-1150.
4. Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985-2016. Breast 2017; 31: 46-50.
5. Corneliussen-James D. Speaking Out On Metastatic Breast Cancer. METAvivor: Metastatic Breast Cancer Research, Support, and Awareness. 2014. Available at: https://www.metavivor.org/blog/speaking-out-on-metastatic-breast-cancer (Accessed: 09.10. 2024).
6. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guidelines. Ann Oncol 2022; 33: 878-892.
7. Müller V, Fuxius S, Steffens CC, et al. Quality of life under capeci­tabine (Xeloda®) in patients with metastatic breast cancer: data from a German non-interventional surveillance study. Oncol Res Treat 2014; 37: 748-755.
8. Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015). Breast 2018; 39: 131-138.
9. de Ligt KM, de Rooij BH, Hedayati E, et al; Innovative Medicines Initiative – Health Outcomes Observatory (H2O) consortium. International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients. Breast Cancer Res Treat 2023; 198: 265-281.
10. Wan BA, Pidduck W, Zhang L, et al. Patient-reported fatigue in breast cancer patients receiving radiation therapy. Breast 2019; 47: 10-15.
11. Meisel JL, Domchek SM, Vonderheide RH, et al. Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 2012; 12: 119-126.
12. Pe M, Dorme L, Coens C, et al. Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncol 2018; 19: e459-e469. DOI: 10.1016/S1470-2045(18)30418-2.
13. Brazee RL, Nugent BD, Sereika SM, Rosenzweig M. The quality of end-of-life care for women deceased from metastatic breast cancer. J Hosp Palliat Nurs 2021; 23: 238-247.
14. Ribi K, Thürlimann B, Schär C, et al. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents – a real-world cross-sectional study from Switzerland (SAKK 95/16). BMC Cancer 2021; 21: 182. DOI: https://doi: 10.1186/s12885-021-07903-8.
15. Karnofsky DA, Burchenal JH. The evaluation of chemotherapeutic agents in cancer. In: McLeod CM (ed.). Evaluation of Chemotherapeutic Agents. New York: University Press; 1949, pp. 191-205.
16. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
17. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). (Version 5.0). Bethesda (Maryland): U.S. Department of Health and Human Services. National Institutes of Health; 2017.
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Natl Cancer Inst 1993; 85: 365-376.
19. Bjelic-Radisic V, Cardoso F, Cameron D, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol 2020; 31: 283-288.
20. Chow E, Nguyen J, Zhang L, et al; European Organization for Research Treatment of Cancer Quality of Life Group. International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases. Cancer 2012; 118: 1457-1465.
21. Arraras J, Garrido E, Pruja E, Marcos M, Tejedor M, Arias F. The EORTC Quality of Life questionnaire QLQ-C30 (2.0 Version). Psychometric study with breast cancer patients. Clinica Salud 2000; 11: 329-349.
22. Arraras JI, Tejedor M, Illarramendi JJ, et al. El cuestionario de calidad de vida para cáncer de mama de la EORTC, QLQ-BR23. Estudio psicométrico con una muestra española. Psic Conduc 2001; 9: 81-98.
23. Gotay CC, Pagano IS. Assessment of Survivor Concerns (ASC): a newly proposed brief questionnaire. Health Qual Life Outcomes 2007; 5: 15. DOI: https://doi: 10.1186/1477-7525-5-15.
24. Mierzynska J, Taye M, Pe M, et al; EORTC and EORTC Breast Cancer Group. Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer 2020; 125: 69-82.
25. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer quality of life questionnaire core 30. J Clin Oncol 2011; 29: 89-96.
26. Lambert-Obry V, Gouault-Laliberté A, Castonguay A, et al. Real- World Patient- and Caregiver-reported Outcomes in Advanced Breast Cancer. Curr Oncol 2018, 25: 282-290.
27. Arraras JI, Nolte S, Liegl G, et al.; EORTC Quality of Life Group. General Spanish population normative data analysis for the EORTC QLQ-C30 by sex, age, and health condition. Health Qual Life Outcomes 2021; 19: 208. DOI: https://doi: 10.1186/s12955-021-01820-x.
28. Scott N, Fayers P, Aaronson N, et al. EORTC QLQ-C30. Reference values. Brussels: EORTC; 2008.
29. Adamowicz K, Baczkowska-Waliszewska Z. Quality of life during chemotherapy, hormonotherapy or antiHER2 therapy of patients with advanced, metastatic breast cancer in clinical practice. Health Qual Life Outcomes 2020; 18: 134. DOI: https://doi:10.1186/s12955-020-01389-x.
30. Vila MM, Barco Berron SD, Gil-Gil M, Ochoa-Arnedo C, Vázquez RV. Psychosocial aspects and life project disruption in young women diagnosed with metastatic hormone-sensitive HER2-negative breast cancer. Breast 2020; 53: 44-50.
31. Delrieu L, Anota A, Trédan O, et al. Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health- related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial. BMC Cancer 2020; 20: 622. DOI: https://doi: 10.1186/s12885-020-07093-9.
32. Willis K, Lewis S, Ng F, Wilson L. The experience of living with metastatic breast cancer – a review of the literature. Health Care Women Int 2015; 36: 514-542.
33. Smith SK, Westbrook K, MacDermott K, Amarasekara S, LeBlanc M, Pan W. Four conversations: a randomized controlled trial of an online, personalized coping and decision aid for metastatic breast cancer patients. J Palliat Med 2020; 23: 353-358.
34. Clemons M, Ong M, Stober C, et al.; REaCT investigators. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer 2021; 142: 132-140.
35. Chapman B, Grunfeld EA, Derakshan N. Quality of working life can protect against cognitive and emotional vulnerability in women living with metastatic breast cancer: a cross-sectional study. J Cancer Surviv 2023; 17: 1295-1308.
36. Lee Mortensen G, Madsen IB, Krogsgaard R, Ejlertsen B. Quality of life and care needs in women with estrogen positive metastatic breast cancer: a qualitative study. Acta Oncol 2018; 57: 146-151.
37. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 2017; 26: 809-815.
38. Dialla PO, Chu WO, Roignot P, Bone-Lepinoy MC, Poillot ML, Coutant C, Arveux P, Dabakuyo-Yonli TS. Impact of age-related socio-economic and clinical determinants of quality of life among long-term breast cancer survivors. Maturitas 2015; 81: 362-370.
39. Ecclestone C, Chow R, Pulenzas N, et al. Quality of life and symptom burden in patients with metastatic breast cancer. Support Care Cancer 2016; 24: 4035-4043.
40. Lo Bianco G, Lanza E, Provenzano S, et al. A multimodal clinical approach for the treatment of bone metastases in solid tumors. Anesth Pain Med 2022; 12: e126333. DOI: https://doi: 10.5812/aapm-126333.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.